Fibroblast Growth Factor–23 and Cardiac Structure and Function

DSpace/Manakin Repository

Fibroblast Growth Factor–23 and Cardiac Structure and Function

Citable link to this page

 

 
Title: Fibroblast Growth Factor–23 and Cardiac Structure and Function
Author: Agarwal, Isha; Ide, Noriko; Ix, Joachim H.; Kestenbaum, Bryan; Lanske, Beate; Schiller, Nelson B.; Whooley, Mary A.; Mukamal, Kenneth J.

Note: Order does not necessarily reflect citation order of authors.

Citation: Agarwal, Isha, Noriko Ide, Joachim H. Ix, Bryan Kestenbaum, Beate Lanske, Nelson B. Schiller, Mary A. Whooley, and Kenneth J. Mukamal. 2014. “Fibroblast Growth Factor–23 and Cardiac Structure and Function.” Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 3 (1): e000584. doi:10.1161/JAHA.113.000584. http://dx.doi.org/10.1161/JAHA.113.000584.
Full Text & Related Files:
Abstract: Background: Fibroblast growth factor–23 (FGF‐23) is a phosphaturic factor previously associated with left ventricular hypertrophy and systolic dysfunction among individuals with chronic kidney disease. Whether FGF‐23 acts directly to induce left ventricular hypertrophy, potentially independent of its klotho coreceptor, remains uncertain. We investigated associations of FGF‐23 with cardiac structural abnormalities among individuals with a broad range of kidney function and explored potential biological mechanisms using cardiac magnetic resonance imaging and histology in klotho‐null mice, an established model of constitutively elevated FGF‐23. Methods and Results: Among 887 participants with coronary artery disease in the Heart and Soul Study, FGF‐23 was modestly associated with worse left ventricular ejection fraction (−1.0% per standard deviation increase in lnFGF‐23; standard error, 0.4%), but was not associated with the overall prevalence of concentric hypertrophy (odds ratio, 1.5; CI, 0.9 to 2.4) or eccentric hypertrophy (odds ratio, 1.1; CI, 0.9 to 1.3). FGF‐23 was only associated with concentric hypertrophy among individuals with diminished kidney function (eGFR <60 mL/min per 1.73 m2; odds ratio, 2.3; CI, 1.0 to 5.3; P‐interaction=0.28). Comparing klotho‐null with wild‐type mice, null mice did not have greater left ventricular mass (P=0.37) or a lower ejection fraction (P=0.94). Conclusions: Together, our results suggest that FGF‐23 is unlikely to have major effects on cardiovascular structure and function among patients free of substantial chronic kidney disease, and these effects may not be independent of the klotho coreceptor.
Published Version: doi:10.1161/JAHA.113.000584
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959672/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:12064415
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters